

## BIOSIG TECHNOLOGIES, INC.

### Three Reasons to Buy BSGM Today

Rob Goldman  
[rob@goldmanresearch.com](mailto:rob@goldmanresearch.com)

December 17, 2015

### BIOSIG TECHNOLOGIES, INC. (OTCQB – BSGM - \$1.24)

Price Target: \$5.00

Rating: Speculative Buy

#### COMPANY SNAPSHOT

BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the \$3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System by filing for FDA 501(k) clearance in 2016 along with an up-list to NASDAQ.

#### KEY STATISTICS

Price as of 12/15/15	\$1.24
52 Week High – Low	\$4.80 - \$1.13
Est. Shares Outstanding	14.7M
Market Capitalization	\$18.2M
3 Mo Avg. Vol.	13,800
Exchange	OTCQB

#### COMPANY INFORMATION

**BioSig Technologies, Inc.**  
8441 Wayzata Blvd.  
Suite 240  
Minneapolis MN 55426  
Phone : 763.999.7330

Website : [www.BioSigTech.com](http://www.BioSigTech.com)  
Email : [info@biosigtech.com](mailto:info@biosigtech.com)

#### INVESTMENT HIGHLIGHTS

**Conclusion: A series of key milestone events next year serve as potential catalysts to drive BSGM's stock from just over \$1 today to \$5 in 2016.** Plus, M&A activity in the medical device market could also favorably impact BSGM's near term and future valuation.

**Catalyst #1: Preclinical study results are expected to be released in 1Q16 which should demonstrate that BioSig Technologies is set to transform its segment of the \$3 billion electrophysiology (EP) marketplace.** We expect results from recent and future studies to indicate that the Company's flagship platform fulfills an unmet need by enhancing the efficacy, diagnostic value, and reduced timeframe of EP studies used in cardiac ablation procedures.

**Catalyst #2: Management noted in a recent shareholder letter that it plans to up-list BSGM's stock to a senior exchange (NASDAQ) during 1H16.** This event should considerably enhance awareness, trading, and valuation of BSGM's shares as prospective institutional investors currently precluded from buying OTC stocks will be able to purchase shares in the only publicly-traded pure-play EP stock.

**Catalyst #3: BSGM plans to file for FDA 510(k) clearance to market its platform in 2H16.** Companies that file for clearance typically receive a big boost in value and the event could be the trigger that ultimately leads to an acquisition of the Company. Big medical device firms have displayed an unquenchable thirst for EP companies with 3 completed M&A deals averaging \$257M in price over the past 12 months alone. That compares with BSGM's current \$19M market cap.

**With a series of milestones ahead, Tier 1 leadership, and high price tags afforded recent acquisitions, our near term target price for the tightly-held BSGM is \$5.** We reiterate our Speculative Buy rating.

## Recent Trading History For BioSig Technologies, Inc. (OTC – BSGM)

(Source: [www.Stockta.com](http://www.Stockta.com))



### Senior Analyst: Robert Goldman

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

### Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report or article, accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

## Disclaimer

This Opportunity Research report was prepared for informational purposes only. *Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats.

Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile, and may offer greater upside. *Goldman Small Cap Research* was compensated by a third party in the amount of \$3500 earlier in the year for the publication and dissemination of a research report and was compensated \$5000 by the Company for a three month research subscription service. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

A *Goldman Small Cap Research* report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR

FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: [www.goldmanresearch.com](http://www.goldmanresearch.com)